Miguel Angel
Pérez. de Juan Romero
![Foto de Miguel Angel](/img/nophoto.png)
![Foto de Heidelberg University](/img/noimage_org.png)
Heidelberg University
Heidelberg, AlemaniaPublicacións en colaboración con investigadores/as de Heidelberg University (1)
2022
-
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial
The Lancet Diabetes and Endocrinology, Vol. 10, Núm. 1, pp. 35-45